发明名称 Semi-allogenic anti-tumour vaccine with HLA haplo-identical antigen-presenting cells
摘要 The present invention relates to semi-allogeneic antigen-presenting cells into which proteins and/or peptides or RNA or DNA or cDNA, respectively, encoding said proteins and/or peptides which are overexpressed in tumor cells or which are derived from autologous tumor cells or different tumor cells or different tumor cell lines have been introduced. Furthermore the invention relates to methods for the generation of these semi-allogeneic antigen-presenting cells as well as to the use thereof in the treatment of tumor diseases.
申请公布号 US9238063(B2) 申请公布日期 2016.01.19
申请号 US201113027827 申请日期 2011.02.15
申请人 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundlheit und Umwelt (GmbH) 发明人 Schendel Dolores;Wank Rudolf
分类号 A61K35/15;A61K35/28;A61K48/00;A61K39/00;C12N5/10;C12N5/078 主分类号 A61K35/15
代理机构 Clark & Elbing LLP 代理人 Clark & Elbing LLP ;Elbing Karen L.
主权项 1. A method of treating a tumor disease in a patient, comprising administering to said patient a therapeutically effective amount of semi-allogeneic HLA-haploidentical antigen presenting cells into which proteins and/or peptides or RNA, DNA, or cDNA encoding said proteins and/or peptides have been introduced, wherein said semi-allogeneic HLA-haploidentical antigen-presenting cells have class I and class II molecules in common with the patient, wherein said proteins and/or peptides are selected from proteins providing a growth advantage to the tumor and/or ensuring its survival, cell cycle regulatory proteins, transcription factors, and proteins involved in the regulation of cell division.
地址 Neuhberg DE